Quarterly report · Q2
7745.TEDINET S100PKQD
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥27.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥51.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥23.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.8bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥1.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥66.3bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥59.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥54.5bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.3bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥32.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥32.0bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥27.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥24.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.9bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥12.8bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥626m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥317m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥741m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥53.43 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.25 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.92 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.02 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.37 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥53.38 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥172.66 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥65.91 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 48.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥13.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥13.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥211m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥370m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥29m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥317m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥245m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥252m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥471m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥470m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥52m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥527m |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥76m |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥8.2bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥845m |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥17.0bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.2bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥817m |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥21.5bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10.1bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥845m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥11.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥11.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥979m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥115m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥68m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥120m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥229m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥274m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥114m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥437m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥437m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥473m |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥7.4bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥155m |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥7.5bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥620m |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥14.6bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥11.6bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥460m |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥18.5bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥10.1bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8.4bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥620m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 620
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1QuarterInstant | 11118000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 12779000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -2000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -2000000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 2482000000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 2918000000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | -0 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | -32000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 368000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 380000000 | JPY |
| Provision for product warranties sga | Prior1YTDDuration | 71000000 | JPY |
| Provision for product warranties sga | CurrentYTDDuration | 73000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 74000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 80000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 2470000000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 2585000000 | JPY |
| Provision for share based remuneration for directors and other officers sga | Prior1YTDDuration | 8000000 | JPY |
| Provision for share based remuneration for directors and other officers sga | CurrentYTDDuration | 9000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02344-000JapanMeasuringInstrumentsReportableSegmentsMember | 7430000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AmericaMeasuringInstrumentsReportableSegmentsMember | 1690000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02344-000EuropeMeasuringInstrumentsReportableSegmentsMember | 437000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AsiaAndOceaniaMeasuringInstrumentsReportableSegmentsMember | 2074000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02344-000MeasuringInstrumentsReportableSegmentsMember | 11632000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02344-000JapanMeasuringInstrumentsReportableSegmentsMember | 1538000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AmericaMeasuringInstrumentsReportableSegmentsMember | 115000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02344-000EuropeMeasuringInstrumentsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AsiaAndOceaniaMeasuringInstrumentsReportableSegmentsMember | 1338000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02344-000MeasuringInstrumentsReportableSegmentsMember | 2992000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02344-000JapanMeasuringInstrumentsReportableSegmentsMember | 8969000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AmericaMeasuringInstrumentsReportableSegmentsMember | 1806000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02344-000EuropeMeasuringInstrumentsReportableSegmentsMember | 437000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AsiaAndOceaniaMeasuringInstrumentsReportableSegmentsMember | 3412000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02344-000MeasuringInstrumentsReportableSegmentsMember | 14625000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02344-000JapanMeasuringInstrumentsReportableSegmentsMember | 155000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AmericaMeasuringInstrumentsReportableSegmentsMember | 68000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02344-000EuropeMeasuringInstrumentsReportableSegmentsMember | 7000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AsiaAndOceaniaMeasuringInstrumentsReportableSegmentsMember | 229000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02344-000MeasuringInstrumentsReportableSegmentsMember | 460000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02344-000JapanSemiconductorRelatedReportableSegmentsMember | 2128000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AmericaSemiconductorRelatedReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02344-000EuropeSemiconductorRelatedReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AsiaAndOceaniaSemiconductorRelatedReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02344-000SemiconductorRelatedBusinessReportableSegmentMember | 2128000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02344-000JapanSemiconductorRelatedReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AmericaSemiconductorRelatedReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02344-000EuropeSemiconductorRelatedReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AsiaAndOceaniaSemiconductorRelatedReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02344-000SemiconductorRelatedBusinessReportableSegmentMember | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02344-000JapanSemiconductorRelatedReportableSegmentsMember | 2128000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02344-000AmericaSemiconductorRelatedReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |